We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA to Expand Least Burdensome Approach Across Product Lifecycle
FDA to Expand Least Burdensome Approach Across Product Lifecycle
The FDA said in a new draft guidance a “least burdensome” approach should be applied throughout the medical device total product lifecycle, rather than just in premarket activities.